China represents the hallmark of EG&S’ international practice. The Firm represents more than a dozen China-based companies that are either publicly-listed in the United States or are seeking to raise debt or equity capital in the United States. Our clients in China include public and private companies operating in a variety of industries, from pharmaceuticals, to agriculture to heavy industry. The Firm also represents many investment banks and investment funds that are seeking to invest in or acting as agents for these companies.
Our China Practice Group has been involved in numerous transactions involving Chinese companies, including initial and secondary public offerings; general corporate and ongoing public company representation; alternative public offerings and reverse mergers; SPACs (including Chardan 2008 Acquisition, the first NASDAQ listed SPAC), PIPEs, private equity and debt financings; venture capital financing; mergers and acquisitions; and joint ventures.
Given our level of activity with Chinese companies over the past several years, we have expanded our China Practice Group to include 5 attorneys that are fluent in Mandarin. We also have attorneys who are fluent in Cantonese and Shanghainese dialects. Three of our attorneys also have law degrees from Chinese universities.
Lawyers from the Firm regularly visit China and speak at conferences on matters related to the Firm's China practice.
The Firm’s international practice stretches beyond China, and our attorneys have experience with companies, transactions and cooperating professionals in:
- Europe (including transactions on the AIM Market in London and Euronext Amsterdam);
- Middle East; and
- Offshore tax-advantaged jurisdictions, including the Cayman Islands, the British Virgin Islands, Guernsey and the Marshall Islands.